Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults

Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults

This first-in-human study (NCT03032588), conducted in Belgium, evaluated a new inactivated poliovirus vaccines (IPV) candidate based on Sabin poliovirus strains grown on the high-yield PER.C6® cell line. Healthy adults (N = 32) were randomized (1:1) to receive a single dose of PER.C6-based Sabin-IPV...

Full description

Bibliographic Details
Main Authors: Isabel Leroux-Roels, Geert Leroux-Roels, Georgi Shukarev, Hanneke Schuitemaker, Conor Cahill, Richard de Rooij, Martin Struijs, Hester van Zeeburg, Jeanne-Marie Jacquet
Format: Article
Language:English
Published: Taylor & Francis Group 2021-05-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
inactivated
poliovirus
vaccine
sabin
ipv
per.c6
Online Access:http://dx.doi.org/10.1080/21645515.2020.1812315

Internet

http://dx.doi.org/10.1080/21645515.2020.1812315

Similar Items